Statin use and survival in 16,098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era

British Journal of HaematologyBrånvall E, Ekberg S, Eloranta S, et al. | August 03, 2021


In patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), improved lymphoma survival was not achieved with statin use, however, statins seemed safe to use during lymphoma treatment.

  • A total 16,098 incident NHL/CLL patients in Sweden from 2007 to 2013 were included.

  • Cox regression was applied.

  • Statin use at diagnosis was reported by 20% of patients.

  • Seemingly, there was no increase in lymphoma-specific mortality in relation to statin use, for actively treated patients with follicular lymphoma.

  • In CLL cases, an association of statin use with all-cause and cardiovascular mortality was evident but there was absence of a consistent link with lymphoma-specific mortality.

  • Using statins during rituximab treatment seemed a safe treatment strategy.

Read the full article on British Journal of Haematology